What is a clinical trial?

A clinical trial is a research study involving human participants designed to evaluate medical interventions — such as drugs, devices, or behavioral strategies. Trials follow a structured protocol and are registered on ClinicalTrials.gov. They progress through phases: Phase 1 (safety), Phase 2 (efficacy), Phase 3 (large-scale comparison), and Phase 4 (post-market surveillance).

How do I find clinical trials I'm eligible for?

You can search ClinicalTrials.gov or use ClinicalMetric to filter by condition, phase, or location. Each trial listing includes eligibility criteria such as age range, sex, diagnosis, and prior treatment history. Contact the study team directly or ask your physician to refer you to a relevant trial.

Are clinical trials safe to participate in?

Clinical trials are conducted under strict ethical and regulatory oversight, including IRB approval and FDA regulation in the US. All participants must give informed consent after reviewing potential risks and benefits. Phase 1 trials carry more uncertainty, while Phase 3 trials involve interventions with an established safety profile. Participation is always voluntary and you may withdraw at any time.

What are the phases of clinical trials?

Clinical trials progress through four main phases. Phase 1 tests safety and dosing in a small group (20–80 people). Phase 2 evaluates efficacy and side effects in a larger group (100–300). Phase 3 compares the intervention against standard treatments in thousands of participants. Phase 4 occurs after approval and monitors long-term effects in the general population.

Do participants get paid for joining clinical trials?

Many clinical trials offer compensation for time and travel expenses, though payment structures vary widely by study. Compensation is not intended to be coercive. Some trials also cover treatment costs for participants. Always review the consent form carefully and ask the study coordinator about any financial considerations before enrolling.

Kidney Disease Clinical Trials 2026: CKD, IgA Nephropathy & Dialysis Alternatives

Medical Notice

This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.

Summary

Chronic kidney disease (CKD) affects approximately 850 million people worldwide and is a leading cause of cardiovascular disease and kidney failure. After decades with few new treatment options, nephrology has seen a wave of approvals and promising trials in 2024–2026: SGLT2 inhibitors for non-diabetic CKD, new therapies for IgA nephropathy, complement inhibitors for rare kidney diseases, and wearable artificial kidney devices. This guide covers the key developments and how to access trials.

SGLT2 Inhibitors: Transforming CKD Treatment

Dapagliflozin (Farxiga) and empagliflozin (Jardiance) are now approved for CKD regardless of diabetes status, based on the DAPA-CKD and EMPA-KIDNEY trials showing significant reduction in kidney function decline and cardiovascular events. In 2026, trials are exploring SGLT2 inhibitors in kidney transplant recipients, patients on dialysis, and in combination with finerenone (a non-steroidal mineralocorticoid receptor antagonist also approved for CKD with diabetes).

IgA Nephropathy Trials

IgA nephropathy is the most common primary glomerulonephritis worldwide and a major cause of kidney failure in young adults. Three drugs have received approval or accelerated approval in 2023–2024:

Sparsentan (Filspari): Combined endothelin and angiotensin receptor blocker, approved for proteinuria reduction in IgA nephropathy
Budesonide (Tarpeyo): Targeted-release oral budesonide reducing IgA production in Peyer's patches, approved 2021
Iptacopan (Fabhalta): Complement factor B inhibitor approved for C3G and IgA nephropathy — Phase 3 confirmatory trials ongoing

Multiple additional Phase 3 trials are recruiting for IgA nephropathy — sibeprenlimab (anti-APRIL), atacicept (anti-APRIL/BAFF), and zigakibart (anti-C3). This is one of the most active areas in nephrology research.

Rare Kidney Disease Trials

Complement inhibitors are transforming treatment for several rare kidney diseases. Avacopan (Tavneos) is approved for ANCA vasculitis. Iptacopan and pegcetacoplan are in trials for C3 glomerulopathy, membranoproliferative GN, and atypical HUS. For patients with rare genetic kidney diseases, whole exome sequencing can identify actionable mutations and match patients to specific trials.

Dialysis and Kidney Replacement Innovation

Wearable artificial kidney devices (WAK) are in Phase 1/2 trials — allowing patients to receive continuous dialysis while ambulatory rather than being tethered to a machine 3×/week. Bioartificial kidney devices combining a hemofilter with living renal tubule cells are in preclinical development. For transplant patients, trials are studying tolerance induction protocols to reduce immunosuppression requirements.